title: Biguanides inhibit complex I, II and IV of rat liver mitochondria and modify their functional properties.
abstract: In this study, we focused on an analysis of biguanides effects on mitochondrial enzyme activities, mitochondrial membrane potential and membrane permeability transition pore function. We used phenformin, which is more efficient than metformin, and evaluated its effect on rat liver mitochondria and isolated hepatocytes. In contrast to previously published data, we found that phenformin, after a 5 min pre-incubation, dose-dependently inhibits not only mitochondrial complex I but also complex II and IV activity in isolated mitochondria. The enzymes complexes inhibition is paralleled by the decreased respiratory control index and mitochondrial membrane potential. Direct measurements of mitochondrial swelling revealed that phenformin increases the resistance of the permeability transition pore to Ca(2+) ions. Our data might be in agreement with the hypothesis of Schäfer (1976) that binding of biguanides to membrane phospholipids alters membrane properties in a non-specific manner and, subsequently, different enzyme activities are modified via lipid phase. However, our measurements of anisotropy of fluorescence of hydrophobic membrane probe diphenylhexatriene have not shown a measurable effect of membrane fluidity with the 1 mM concentration of phenformin that strongly inhibited complex I activity. Our data therefore suggest that biguanides could be considered as agents with high efficacy but low specifity.
authors.affiliation: Centre of Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic. monika.cahova@ikem.cz.
authors.forename: Z
authors.initials: Z
authors.lastname: Drahota
authors.forename: E
authors.initials: E
authors.lastname: Palenickova
authors.forename: R
authors.initials: R
authors.lastname: Endlicher
authors.forename: M
authors.initials: M
authors.lastname: Milerova
authors.forename: J
authors.initials: J
authors.lastname: Brejchova
authors.forename: M
authors.initials: M
authors.lastname: Vosahlikova
authors.forename: P
authors.initials: P
authors.lastname: Svoboda
authors.forename: L
authors.initials: L
authors.lastname: Kazdova
authors.forename: M
authors.initials: M
authors.lastname: Kalous
authors.forename: Z
authors.initials: Z
authors.lastname: Cervinkova
authors.forename: M
authors.initials: M
authors.lastname: Cahova
mesh_terms: D000818:Animals; D001645:Biguanides / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D042967:Electron Transport Complex I / Q000037:antagonists & inhibitors / Q000502:physiology*; D042963:Electron Transport Complex II / Q000037:antagonists & inhibitors / Q000502:physiology*; D003576:Electron Transport Complex IV / Q000037:antagonists & inhibitors / Q000502:physiology*; D004791:Enzyme Inhibitors / Q000494:pharmacology; D008297:Male; D008687:Metformin / Q000494:pharmacology; D008930:Mitochondria, Liver / Q000187:drug effects / Q000201:enzymology*; D010629:Phenformin / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar
chemical_list: D001645:Biguanides; D004791:Enzyme Inhibitors; D008687:Metformin; D010629:Phenformin; D042963:Electron Transport Complex II; D003576:Electron Transport Complex IV; D042967:Electron Transport Complex I